LUCIUS 卢修斯 劳拉替尼 Lorlatinib ALK阳性肺癌

劳拉替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Lorlatinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

LUCIUS

ALK阳性肺癌

Each film-coated LuciL.orla tablet contains:
Indication

PHARMACEUTICALS

LnciLorla is for the treatment of adult patients
with metastatic non-small cell lung cancer

LuciLorla

Recommended dosage: 100 mg orally once daily
Severe Renal Impairment: 75 mg oraly once

Lorlatinib Tablets

Tablets should be swallówed whole & n

chewedor crochednot

Rx Only

FDA批准

Storage: in a dry place and store at 20℃ to 25℃

25mg

Warning:
Keep medicine out of the reach of Children. D
not administered LuciLorla in Pregnancy and
Lactation patient treatment.
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by
LUCIUS

Thongmang village, Xaythany district

权威认证

Vientiane Capital, Laos
www.lucius.la
Warning and Precaution: 10 Dc sow
by retail on prescription of a kegistered

ony, and as directed by the

30 Tablets

口碑质量

适用于治疗成年转移性非小细胞肺癌 NSCLC)患者,

其肿瘤经检测呈间变性淋巴瘤激酶(ALK)阳性。

推荐剂量:
1、每日1次:每次口服100mg;
2、严重肾损伤:每日一次,每次口服75mg。